NMNAT-3 CRISPR/Cas9 KO Plasmid (h): sc-403839

Overview

NMNAT3 encodes nicotinamide mononucleotide adenylyltransferase 3 (NMNAT-3), a mitochondrial enzyme that catalyzes the final step of NAD+ biosynthesis from nicotinamide mononucleotide, sustaining organellar NAD+ pools required for oxidative metabolism. By controlling NAD+-dependent redox reactions and supporting sirtuin- and PARP-linked signaling, NMNAT-3 influences mitochondrial homeostasis, cellular stress responses, and energy balance. Altered NMNAT3 activity has been associated with dysregulated NAD+ metabolism and mitochondrial dysfunction, processes implicated in neurodegeneration, cardiometabolic disorders, and tumor cell metabolic adaptation. As a mitochondrial NAD+ node, NMNAT-3 is relevant for studies of bioenergetics, mitochondrial maintenance, and NAD+-coupled signaling pathways.

NMNAT-3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the NMNAT3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the NMNAT3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the NMNAT3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish NMNAT-3 protein expression.

This CRISPR knockout system enables efficient generation of NMNAT3-deficient cell models for investigation of NMNAT-3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

Key Features

• sgRNAs targeting NMNAT3 exon(s) critical for NMNAT-3 function
• Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
• GFP reporter for identification of transfected cells
• Pool of plasmids targeting multiple NMNAT3 genomic sites to improve knockout efficiency
• Compatible with delivery by transfection

Design Variants

CRISPRs +/- HDRs

• gRNAs encoded by NMNAT-3 CRISPR/Cas9 KO Plasmid (h) and NMNAT-3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the NMNAT3 locus. One or both targeting designs may be available. See Related Products for availability.
• HDR donor constructs encoded by NMNAT-3 HDR Plasmid (h) and NMNAT-3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by NMNAT3 homology arms to support homology-directed repair at defined NMNAT3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.